Barclays
CAMP icon

Barclays’s CAMP4 Therapeutics CAMP Stock Holding History

Barclays’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$153K Sell
34,693
-38,908
-53% -$185K ﹤0.01% 3835
2025
Q4 		$451K Buy
73,601
+73,531
+105,044% +$313K ﹤0.01% 3905
2025
Q3 		$210 Buy
+70
New +$130 ﹤0.01% 5240
2025
Q2 		– Sell
-7,508
Closed -$30K – 5281
2025
Q1 		$30K Sell
7,508
-3,162
-30% -$15.3K ﹤0.01% 4721
2024
Q4 		$55.7K Buy
+10,670
New +$87.7K ﹤0.01% 4739

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Barclays's CAMP Position: Q1 2026 in Review

Barclays reduced its CAMP4 Therapeutics (CAMP) stake by 53% in Q1 2026, selling an estimated $185K and leaving 34,693 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #3835.

Barclays first reported a position in CAMP in Q4 2024 and has held it in 5 quarters since. The position peaked at $451K in Q4 2025. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • Barclays held 34,693 shares of CAMP4 Therapeutics worth $153K as of Q1 2026.
  • Barclays sold 38,908 CAMP4 Therapeutics shares in Q1 2026, an estimated $185K.
  • CAMP4 Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3835 holding.
  • Barclays first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Barclays's CAMP4 Therapeutics position peaked at $451K in Q4 2025.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.